Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 2/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | CPB1 | P15086 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1176585 | 1.00 | TACR1 (0.42) | TACR1KCNQ2MGLLNAAATSHR | |
| SCHEMBL1176583 | 1.00 | TACR1 (0.42) | TACR1KCNQ2MGLLNAAATSHR | |
| SCHEMBL1176581 | 1.00 | TACR1 (0.42) | TACR1KCNQ2MGLLNAAATSHR | |
| SCHEMBL5820901 | 1.00 | TACR1 (0.42) | TACR1KCNQ2MGLLNAAATSHR | |
| SCHEMBL5474181 | 0.89 | TACR1 (0.41) | TACR1KCNQ2MGLLNAAATSHR | |
| SCHEMBL14597712 | 0.89 | TACR1 (0.41) | TACR1KCNQ2MGLLNAAATSHR | |
| SCHEMBL8060970 | 0.89 | KCNQ2 (0.46) | TACR1KCNQ2MGLLNAAATSHR | |
| SCHEMBL8060977 | 0.89 | KCNQ2 (0.46) | TACR1KCNQ2MGLLNAAATSHR | |
| SCHEMBL8060971 | 0.89 | KCNQ2 (0.46) | TACR1KCNQ2MGLLNAAATSHR | |
| SCHEMBL8996389 | 0.88 | HSD17B2 (0.45) | NAAAHSD17B2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1607389-A1 | 4-protected-amino-2-substituted-1,2,3,4-tetrahydroquinolines as intermediates for CETP inhibitors | Pfizer Products Inc. (US) | 2005-12-21 | — | — | EP | claimed |
| US-6197786-B1 | ANTICHOLESTEROL AGENTS | PFIZER INC | 2001-03-06 | — | — | US | claimed |
| EP-1730152-B1 | TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20080269284-A1 | Compounds and Methods for Treating Dyslipidemia | ELI LILLY AND COMPANY (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269284-A1 | Compounds and Methods for Treating Dyslipidemia | ELI LILLY AND COMPANY (US) | 2008-10-30 | — | — | US | disclosed |
| US-20070082896-A1 | Tetrahydroquinoline derivatives and a process for preparing the same | TANABE SEIYAKU CO., LTD. | 2007-04-12 | — | — | US | disclosed |
| EP-1761521-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2007-03-14 | — | — | EP | disclosed |
| US-20060270675-A1 | Inhibitors of cholesterol ester transfer protein | ARRAY BIOPHARMA INC. | 2006-11-30 | — | — | US | disclosed |
| US-20060063803-A1 | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds | PFIZER INC | 2006-03-23 | — | — | US | disclosed |
| WO-2006012093-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-02-02 | — | — | WO | disclosed |
| EP-1383734-B1 | COMPOUNDS USEFUL AS INTERMEDIATES FOR 4-AMINOQUINOLINE DERIVATIVES | PFIZER PROD INC (US) | 2006-02-01 | — | — | EP | disclosed |
| US-6489478-B1 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INHIBITORS AND THE USE OF SUCH INHIBITORS TO ELEVATE CERTAIN PLASMA LIPID LEVELS, INCLUDING HIGH DENSITY LIPOPROTEIN-CHOLESTEROL AND TO LOWER CERTAIN | PFIZER INC. | 2002-12-03 | — | — | US | disclosed |
| EP-1246804-A1 | 4-CARBOXYAMINO-2-ETHYL-1,2,3,4-TETRAHYDROQUINOLINE CRYSTAL AS CETP INHIBITOR | Pfizer Products Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
| US-20020035125-A1 | Therapeutic combination | SHEAR CHARLES L (US) | 2002-03-21 | — | — | US | disclosed |
| WO-2002013797-A2 | THERAPEUTIC COMBINATION OF A CETP INHIBITOR AND ATORVASTATIN | PFIZER PRODUCTS INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| US-6313142-B1 | AS CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITOR; FOR THERAPY OF ATHEROSCLEROSIS, PERIPHERAL VASCULAR DISEASE, DYSLIPIDEMIA, HYPERBETALIPOPROTEINEMIA, HYPOALPHALIPOPROTEINEMIA, HYPERCHOLESTEROLEMIA | PFIZER INC. | 2001-11-06 | — | — | US | disclosed |
| EP-1125929-A1 | Method for making (-)-(2R,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonylamino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2001040190-A1 | 4-CARBOXYAMINO-2-ETHYL-1,2,3,4-TETRAHYDROQUINOLINE CRYSTAL AS CETP INHIBITOR | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| US-6197786-B1 | ANTICHOLESTEROL AGENTS | PFIZER INC | 2001-03-06 | — | — | US | disclosed |
| US-6140343-A | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS WHICH ARE USED TO ELEVATE HIGHDENSITY LIPOPROTEIN-CHOLESTEROL AND TO LOWER LOW DENSITY LIPOPROTEIN-CHOLESTEROL AND TRIGLYCERIDES; FOR TREATING ATHEROSCLEROSIS, PERIPHERAL VASCULAR DISEASE, OBESITY | PFIZER (US) | 2000-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082896-A1 | Tetrahydroquinoline derivatives and a process for preparing the same | CETP, MTTP, NPC1L1 | TACR1 2517/4885KCNQ2 602/4885MGLL 222/4885 |
| US-20060270675-A1 | Inhibitors of cholesterol ester transfer protein | CETP, LCAT, MTTP | TACR1 3695/4885KCNQ2 2879/4885MGLL 81/4885 |
| US-20060063803-A1 | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds | APOB, LDLR, CETP | TACR1 4584/4885KCNQ2 662/4885MGLL 306/4885 |
| US-20020035125-A1 | Therapeutic combination | CETP, HMGCR, PCSK9 | TACR1 1161/4885KCNQ2 2965/4885MGLL 178/4885 |
| US-20080269284-A1 | Compounds and Methods for Treating Dyslipidemia | APOB, PCSK9, LIPC | TACR1 504/4885KCNQ2 565/4885MGLL 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.